Olympus America Inc.

Olympus America Inc. is the U.S. head-office and medical-equipment sales entity of Olympus Corporation of the Americas, a wholly owned subsidiary of Tokyo-based Olympus Corporation (TSE: 7733; founded 1919). Its address is 3500 Corporate Parkway, Center Valley, Pennsylvania. Olympus Corporation of the Americas states it employs more than 4,500 people across North and South America (olympusamerica.com); the global parent reported revenue of ¥936.2 billion and roughly 28,800–29,300 employees for the fiscal year ended March 31, 2024 (Olympus annual securities report; third-party profiles). No separate revenue figure for Olympus America Inc. is publicly disclosed.

Operations. The parent is a medical technology company built on endoscopy. Its Endoscopic Solutions business sells gastrointestinal and surgical endoscopes; its Therapeutic Solutions business sells GI treatment instruments, urology, respiratory, energy, otolaryngology and gynecology devices. Olympus divested non-medical lines: the consumer camera business went to Japan Industrial Partners in 2021, and the Scientific Solutions business (biological/industrial microscopes, industrial videoscopes, non-destructive testing) was transferred to Bain Capital in April 2023 as Evident Corporation (Olympus/Bain press releases).

Litigation posture. In the tracked data Olympus America is a two-way litigant in a single 2018 dispute: defendant in two consolidated Delaware actions and plaintiff in one. This reflects an operating company that counter-punched rather than a volume filer or an NPE. All three cases sit in the District of Delaware — not a plaintiff-friendly Texas venue — and all involve the same counterparty.

Notable cases. Maxell, Ltd. (formerly Hitachi Maxell, an operating media/battery company that also runs an active patent-licensing program) sued Olympus Corporation and Olympus America in D. Del. on Feb. 23, 2018 (No. 1:18-cv-00310), asserting camera-imaging patents against Olympus digital camera models (OM-D E-M1 Mark II, Pen-F, Tough TG, Air A01). Olympus had already filed a declaratory-judgment action (No. 1:18-cv-00216) on Feb. 6, 2018 and petitioned for IPR of related Maxell patents. Maxell counterclaimed on ten patents, including the '102 patent; in November 2018 the court denied Olympus's §101 motion on that patent. Outcomes beyond those rulings are not reflected in the tracked data.